NASDAQ$PHAT
Phathom Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Phathom Pharmaceuticals reported third quarter 2023 results, highlighted by the FDA approval of VOQUEZNA for Erosive GERD and the submission of an NDA for vonoprazan as a daily treatment for Non-Erosive GERD.
Phathom Pharmaceuticals reported a net loss of $43.2 million for the third quarter of 2023. The company highlighted the FDA approval of VOQUEZNA for Erosive GERD and the submission of an NDA for vonoprazan as a daily treatment for Non-Erosive GERD.
- VOQUEZNA approved by the FDA for Erosive GERD treatment and associated heartburn relief.
- Commercial availability of VOQUEZNA for Erosive GERD and H. pylori is expected in December 2023.
- NDA submitted to the FDA for vonoprazan as a once-daily treatment for Non-Erosive GERD.
- Company believes it is well capitalized to support the blockbuster potential of VOQUEZNA, with an additional $175 million in cash provided under a non-dilutive revenue interest financing agreement.
Headline financials
Revenue & EPS history
Phathom · Revenue · Quarterly
$0
Forward guidance
Phathom believes it will have sufficient capital to fund operations through the end of 2025.
Tailwinds
- Expected product revenues
- Funds available under its existing term loan with Hercules
- Cash to be paid under our royalty interest financing agreement based on the recent approval of VOQUEZNA for Erosive GERD
- VOQUEZNA FDA approval for Erosive GERD
- NDA submission for vonoprazan as a daily treatment for Non-Erosive GERD
Headwinds
- We may not be able to successfully commercialize VOQUEZNA which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers
- Future data generated from our stability program may be different from the data submitted to the FDA to date and may not demonstrate that our mitigation efforts will continue to maintain the level of the nitrosamine impurity below the acceptable intake (AI) level throughout the shelf life of products containing vonoprazan, which could result in market action or shelf life reduction
- Risks associated with product manufacturing or formulation changes required to be made in connection with achieving the AI
- The inherent risks of clinical development of vonoprazan
- Phathom’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-2.2%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-0.4%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+10.0%
Q1 2023
Best reaction
-22.8%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | +6.9% | -18.6% | |
| Q4 2025 | +9.9% | -10.3% | -14.1% | |
| Q3 2025 | -1.8% | +8.1% | +9.8% | |
| Q1 2025 | -21.7% | -44.1% | -0.9% | |
| Q4 2024 | -3.0% | -21.2% | -19.7% | |
| Q3 2024 | -6.3% | -47.1% | -50.0% | |
| Q2 2024 | +8.7% | +12.6% | +63.9% | |
| Q1 2024 | -5.6% | +2.9% | +5.0% | |
| Q4 2023 | -8.7% | -16.0% | +13.4% | |
| Q3 2023 | -4.0% | -9.2% | +7.8% | |
| Q2 2023 | +3.0% | +2.0% | -15.8% | |
| Q1 2023 | +10.0% | +5.0% | +8.3% | |
| Q4 2022 | -7.1% | -10.0% | -29.9% | |
| Q3 2022 | -9.8% | +4.0% | +5.3% | |
| Q2 2022 | -22.8% | -20.1% | -3.6% | |
| Q1 2022 | -6.3% | -10.5% | -19.7% | |
| Q4 2021 | +2.0% | -4.2% | -24.9% | |
| Q3 2021 | +1.7% | -2.4% | -13.7% | |
| Q2 2021 | +1.5% | -0.1% | +6.6% | |
| Q1 2021 | +6.4% | +0.9% | +5.9% | |
| Q4 2020 | +3.6% | +1.9% | +9.8% | |
| Q3 2020 | -8.6% | -3.0% | +12.6% | |
| Q2 2020 | +5.1% | +12.2% | +5.3% | |
| Q1 2020 | -0.9% | -1.4% | +24.1% | |
| Q4 2019 | -3.2% | -3.2% | +13.5% | |
| Q3 2019 | +6.5% | +9.1% | +9.0% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro